Archive · 3 Dec 2025
Corona Remedies IPO Opens December 8
Corona Remedies, an Indian pharmaceutical company, is opening its IPO for public subscription from December 8 to December 10.
The price band is set between ₹1,008 and ₹1,062 per share, with a minimum lot size of 14 shares.
The IPO is an Offer for Sale (OFS), meaning the company won't receive any funds; instead, promoters and existing investors will sell their shares.
The total issue size is ₹655.37 crore.
The company is known for its fast growth in the pharmaceutical market, specializing in areas like women's health and pain management.
The shares are expected to be listed on December 15.
Corona Remedies IPO opens for subscription on December 8, 2023, with a price band of ₹1,008-1,062 per share.
The IPO is an Offer for Sale (OFS) of 61.71 lakh shares totaling ₹655.37 crore, with no funds going to the company.
Allocation is 35% for retail investors, 50% for qualified institutional buyers, and 15% for non-institutional investors.
The company is recognized as the second fastest-growing among top 30 Indian Pharmaceutical Market players with a CAGR of 16.77% in domestic sales.
Corona Remedies specializes in branded pharmaceutical formulations, focusing on women's healthcare, cardio-diabetes, pain management, and urology.
- Who
- Corona Remedies, a pharmaceutical company
- What
- IPO opening for subscription
- When
- December 8-10, 2023
- Where
- India (BSE and NSE listing)
- Why
- To allow promoters and existing investors to sell shares via OFS
- IPO Price Band
- ₹1,008 to ₹1,062 per share
- IPO Dates
- Subscription: Dec 8-10, Allotment: Dec 11, Listing: Dec 15
- Issue Size
- ₹655.37 crore (OFS of 61.71 lakh shares)
- Lot Size
- 14 shares (₹14,868 at upper band)
- Allocation
- 35% retail, 50% QIB, 15% NII
- Lead Managers
- JM Financial, IIFL Capital, Kotak Capital
- Registrar
- Bigshare Services
- Company Focus
- Women's health, cardio-diabetes, pain management, urology
